Yichang HEC ChangJiang Pharmaceutical Co Ltd
01558
Company Profile
Business description
Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product. Its products include Kewei, Ertongshu, Xinhaining, Oumeining, and Xining.
Contact
No. 38 Binjiang Road
Yidu, Hubei Province
Yichang
CHNSector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,861
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
stocks
Insignia Financial: Revised deal still attractive
The offer price is well above our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,979.40 | 22.00 | -0.24% |
| CAC 40 | 7,874.64 | 24.21 | 0.31% |
| DAX 40 | 24,476.31 | 235.49 | 0.97% |
| Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
| FTSE 100 | 9,152.53 | 91.04 | 1.00% |
| HKSE | 25,667.18 | 129.11 | 0.51% |
| NASDAQ | 21,020.02 | 127.33 | 0.61% |
| Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
| NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
| S&P 500 | 6,358.91 | 49.29 | 0.78% |
| S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
| SSE Composite Index | 3,605.73 | 23.43 | 0.65% |